Nitazoxanide and Probiotics for the Treatment of Recurrent Clostridium difficile Infection in a Peritoneal Dialysis Patient

被引：4

作者：

Yangco, Bienvenido G.

Sher, Gulab

Bardin, Matthew C.

机构：

[1] Adv Care Hospitalists, Tampa, FL USA

[2] S Florida Baptist Hosp, Plant City, FL USA

[3] Romark Inst Med Res, Tampa, FL USA

来源：

SOUTHERN MEDICAL JOURNAL | 2009年 / 102卷 / 07期

关键词：

Clostridium difficile; dialysis; nitazoxanide; peritoneal dialysis; probiotic;

D O I：

10.1097/SMJ.0b013e3181a82bbb

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nitazoxanide has been proven to be efficacious for the treatment of Clostridium difficile infection (CDI), but data is limited in peritoneal dialysis (PD) patients. This report details the successful utilization of nitazoxanide and probiotics to treat multirecurrent CDI in a PD patient. A 58-year-old woman was admitted with hypotension, nausea and vomiting attributed to metronidazole therapy for CDI, her third CDI treatment regimen in 3 months. During her admission, the patient developed CDI and was started on a 6-week regimen of nitazoxanide and probiotics to assist in re-establishing the colonic flora. The regimen was well tolerated and the patient remained disease free at follow up, four months later.

引用

页码：746 / 747

页数：2

共 8 条

[1] Treatment of Clostridium difficile infection
Gerding, Dale N.
Muto, Carlene A.
Owens, Robert C., Jr.
[J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 : S32 - S42
[2] In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004
Hecht, David W.
Galang, Minerva A.
Sambol, Susan P.
Osmolski, James R.
Johnson, Stuart
Gerding, Dale N.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) : 2716 - 2719
[3] RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SACCHAROMYCES-BOULARDII IN COMBINATION WITH STANDARD ANTIBIOTICS FOR CLOSTRIDIUM-DIFFICILE DISEASE
MCFARLAND, LV
SURAWICZ, CM
GREENBERG, RN
FEKETY, R
ELMER, GW
MOYER, KA
MELCHER, SA
BOWEN, KE
COX, JL
NOORANI, Z
HARRINGTON, G
RUBIN, M
GREENWALD, D
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (24): : 1913 - 1918
[4] Clostridium difficile:: Recent epidemiologic findings and advances in therapy
McMaster-Baxter, Nicole L.
Musher, Daniel M.
[J]. PHARMACOTHERAPY, 2007, 27 (07): : 1029 - 1039
[5] Clostridium difficile colitis that fails conventional metronidazole therapy:: response to nitazoxanide
Musher, Daniel M.
Logan, Nancy
Mehendiratta, Vaibhav
Melgarejo, Nicolas A.
Garud, Sagar
Hamill, Richard J.
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (04) : 705 - 710
[6] Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double-Blind Study
Musher, Daniel M.
Logan, Nancy
Bressler, Adam M.
Johnson, David P.
Rossignol, Jean-Francois
[J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (04) : E41 - E46
[7] Probiotics for treatment of Clostridium difficile-associated colitis in adults
Pillai, A.
Nelson, R.
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):
[8] Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients
Rossignol, J. -F.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (05) : 887 - 894

← 1 →